Clinical trials: Dementia Alzheimers
Alzheimer Disease
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
The purpose of this study is to test a new technique that may, in the future, help deliver medications to the brain of people with Alzheimer's disease.
- Trial name
- NCT04118764
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Definity, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Alzheimer's Disease, Vascular Dementia
Seroquel- Agitation Associated With Dementia
The purpose of this study is to determine how safe and effective Seroquel (quetiapine fumarate) is compared to placebo (a non-drug tablet) for a period of up to 10 weeks in the treatment of agitation symptoms in nursing home or…
- Trial name
- NCT00621647
- Testing
- Quetiapine Fumarate
- Volunteers
- 333 people
- Sponsor
- AstraZeneca
Alzheimer's Disease (AD), Dementia
δ in Dementia Clinical Trials
The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline.
- Conditions
- Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
- Trial name
- δND (NCT05592678)
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Obstructive Sleep Apnea (OSA), Mild Cognitive Impairment (MCI)
CPAP Randomized Controlled Trial
The overall goal of this randomized controlled trial is to test the hypothesis that in older adults with mild cognitive impairment (MCI) and previously untreated obstructive sleep apnea (OSA), 4 months of web-based sleep…
- Conditions
- Obstructive Sleep Apnea (OSA), Mild Cognitive Impairment (MCI), Cognitive Decline Prevention in Pre-frail Older Adults
- Trial name
- NCT06773416
- Testing
- CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health, Delayed CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health
- Where
- Canada
- Volunteers
- 206 people
- Sponsor
- Sunnybrook Health Sciences Centre
Alzheimer Disease
Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease
The goal of this study is to explore the efficacy and safety of near-infrared light combined with lecanemab in patients with mild Alzheimer's disease (AD).
- Trial name
- NCT06992804
- Testing
- NirsCure with Lecanemab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer Disease
Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program
Caring for patients with Alzheimer Disease or Related Disorders (ADRD) is accompanied with a caregiver burden that increases with the progression of the disease.
- Trial name
- PHARMAID (NCT02802371)
- Testing
- Psychosocial intervention, Pharmaceutical care and psychosocial support
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Hospices Civils de Lyon
Alzheimer's Disease
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
- Trial name
- NCT02051764
- Testing
- Flortaucipir F18, Florbetapir F 18, Brain PET Scan
- Where
- 4 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 3
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
- Trial name
- ADNI3 (NCT02854033)
- Where
- 59 sites in United States, Canada
- Volunteers
- 1,141 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Healthy Volunteers
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF)…
- Trial name
- NCT01807026
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
The Feasibility and Effect of Digital Cognitive Training in Mild Cognitive Impairment
The goal of this study is to assess the feasibility and effect of digital cognitive training based on the principles of Differential Outcome Training (DOT) in patients with Mild Cognitive Impairment.
- Trial name
- NCT06399978
- Testing
- Brain Blossom - Gamified Differential Outcome Training, Gamified Non-Differential Outcome Training
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Pernille Louise Kjeldsen
Haemorrhagic Stroke, Ischaemic Stroke
Digital Application for Stroke Health
Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge.
- Conditions
- Haemorrhagic Stroke, Ischaemic Stroke, Transient Ischemic Attack (TIA)
- Trial name
- DASH (NCT07511868)
- Testing
- StrokeApp, Standard care
- Where
- 7 sites in Austria
- Volunteers
- 500 people
- Sponsor
- VASCage GmbH
Alzheimer Disease
Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
- Trial name
- NCT05731440
- Testing
- 18F-Fluselenamyl
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer's Disease, Huntington Disease
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day.
- Trial name
- NCT00988624
- Testing
- Dimebon IR Tablet, Dimebon MR1, Dimebon MR2
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Mild Cognitive Impairment, Alzheimer Disease
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center.
- Trial name
- BVB (NCT03136679)
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Alzheimer's Disease, Cardiovascular Risk Factors
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease
Three quarters of patients with Alzheimer's disease have at least one vascular risk factor (VRF). Vascular brain lesions are present in most Alzheimer's patients (especially older ones).
- Trial name
- COVARAD (NCT01423396)
- Testing
- optimal care of VRF, standard care
- Where
- 21 sites in France
- Volunteers
- 304 people
- Sponsor
- University Hospital, Lille
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia…
- Trial name
- NCT05834296
- Testing
- ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alzamend Neuro, Inc.
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.